Developing alternative routes of immunotherapies with innovative drugs for neurodegenerative diseases.
In the Media
Company
Our Mission
Our mission is to bring breakthrough therapies to patients with the aim of treating Non-Active Secondary Progressive Multiple Sclerosis, Alzheimer’s, ALS and other neuroinflammatory and neurodegenerative indications to optimize health outcomes.
Pipeline
Clinical Candidates
Our major clinical assets are supported by extensive worldwide issued patents and pending patent applications covering composition of matter, formulation technologies, manufacturing processes and disease indications.
Lead Asset is Intranasal Foralumab
Multiple administration routes of a proven systemic anti-inflammatory, patent protected until 2040
Non-active SPMS*
Phase 2a began in 3Q 2023*Non-Active Secondary Progressive Multiple Sclerosis (expanded access program; n=10).
Alzheimer's
IND clearance received in 3Q 2023
Long COVID
IND planned
Early Onset Type 1 DM
ALS*
* Grant from Amyotrophic Lateral Sclerosis Association for development
Intracerebral Hemorrhage (ICH)
*Non-Active Secondary Progressive Multiple Sclerosis (expanded program; n=10) ** Grant from Amyotrophic Lateral Sclerosis Association for development
Foralumab TZLS-401
Foralumab is the only fully human anti-CD3 monoclonal antibody (mAb) for treatment of Neuroinflammatory and Neurodegenerative indications.
Anti IL-6 Receptor mAb
(IL-6R:TZLS-501)
We are developing a fully human monoclonal antibody (mAb) targeting the receptor for IL-6 as a potential treatment for lung diseases.
Clinical Trials
Tiziana is currently conducting clinical trials using intranasal Foralumab for Non-Active Secondary Progressive Multiple Sclerosis.
Anti IL-6R mAb (TZLS-501)
Manufacturing of clinical supplies for a Phase 1 study is anticipated to be completed in 4Q 2022.
Milciclib
We are exploring a study to evaluate the combination of milciclib and gemcitabine in NSCLC subjects with associated pan KRAS-positive mutations.